NCT02569320View on ClinicalTrials.gov

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 20, 2016

Primary Completion Date

November 14, 2020

Study Completion Date

March 10, 2021

Conditions
Recurrent Plasma Cell Myeloma
Interventions
DRUG

Dexamethasone

Given PO

DRUG

HDAC Inhibitor AR-42

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pomalidomide

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT02569320 - HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter